“NVIDIA is outstanding in the areas that matter most for AI-enabled science: accelerated computing, AI training and inference, and Physical AI,” Luciano Lucas, VP and enterprise head of autonomous and intelligent labs at Danaher, toldBioXconomy.
“It is a world leader with clear strategic advantages across many markets, including life sciences. Danaher brings an equally critical position: scale and trust across the life sciences and diagnostics ecosystem, a broad portfolio of life sciences instruments, differentiated digital businesses, automation know-how, customer proximity and the experimental data environments where AI can be converted into evidence.”
Thearrangement combinesDanaher’s instrument and lab automation portfolio with NVIDIA’s computing infrastructure andAIsoftware. The underlying premise is that AI models can generate hypotheses or predictions faster than labs can currently test them, and that building AI processing into the instruments themselves could shorten that cycle – feeding experimental results back into models and using model output to guide subsequent experiments.
Specifics of the technical approach include running NVIDIA’s DGX Spark hardware at the edge – closer to the instruments generating data – rather than relying solely on centralized or cloud compute. The companies also plan to use NVIDIA’s RAPIDS libraries for faster data processing and are evaluating foundation models. This includes NVIDIA’s BioNeMo for real-time analysis tasks. A more exploratory piece of the collaboration involves NVIDIA’s Cosmos world models and Omniverse digital twin technology, which could eventually be used to simulate instrument behavior or lab conditions before physical experiments run.
“No single company will deliver the future of AI-enabled science alone,” Lucas commented. “Success will require capabilities across instruments, software, automation, data, AI, compute and laboratory operations. Danaher is a leader in the physical and digital infrastructure of life sciences, operating at the interface of biology, instrumentation, scientific software, clinical and diagnostic workflows, and customer needs. NVIDIA can extend what is possible at the AI and compute layer; Danaher can help shape how those capabilities are applied in real scientific, clinical and operational settings.”
Danaher said the initial rollout will target a limited set of instruments rather than its full product line, with broader deployment contingent on how that pilot work performs. The company also noted that customers using its instruments will retain the ability to choose their own AI models and data standards, rather than being locked into NVIDIA’s stack exclusively.
“This does not replace scientists or remove the need for validation. Science still advances through evidence. The opportunity is to reduce the time and complexity between an AI-generated idea and the experimental evidence needed to act on it,” Lucas told us.
“The collaboration therefore matters at two levels. Near term, it focuses on priority instruments and the technologies named in the announcement: edge computing, accelerated analytics, real-time inference, scientific reasoning and foundation models. Longer term, it points toward more adaptive laboratory workflows where instruments, models and experimental data learn from one another over time.”
Investival Showcase USA brings visionary life-science innovators together to secure game-changing capital and partnerships.
